Health care costs are straining resources in most countries. Payers are looking for ways to manage these costs. Drug companies can be blindsided by negative reimbursement treatment even when physicians are enthusiastic about a new drug.

To avoid such surprises, many pharmaceutical and biotech companies are wrestling with reimbursement issues earlier in the development process. To help, Equinox Group has developed the Equinox Group Reimbursement Index. This module of our DTA tool does not predict the exact reimbursement treatment of an agent in a country but offers early insight into the degree of reimbursement friction a product profile is likely to encounter.